A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

Sponsor:

Seattle Genetics, Inc.

Sponsor Study ID:

SEA-CD70

CTO #:

103164

NCT Number:

NCT04227847

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Myeloid and Monocytic Leukemia

Study Objectives:

This is a phase 1, open-label, multicenter, dose-escalation, and cohort expansion study designed to evaluate the safety, tolerability, PK, and antitumor activity of SEA-CD70 in adults with myeloid malignancies. The study will be conducted in up to 3 parts. Part A is a dose escalation cohort designed to identify the MTD or recommended expansion dose of SEA-CD70 in subjects with relapsed/refractory (HMA-failure) MDS. Part B is an expansion cohort designed to evaluate the safety and tolerability of SEA-CD70 in subjects with relapsed/refractory (HMA-failure) MDS. Part C is an expansion cohort designed to evaluate the safety and tolerability of SEA-CD70 in subjects with relapsed/refractory AML.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)